Q4 2025 Management View Sean Saint, President and CEO, reflected on the company's first full year as a public entity, highlighting, "Close to 20,000 new users adopted our technology in 2025, more than ...

Beta Bionics (NASDAQ:BBNX) reported fourth-quarter and full-year 2025 results on its earnings call Tuesday, highlighting ...

Beta Bionics, Inc., a leader in diabetes management solutions, announced it will release its first quarter financial results for 2025 on May 6, 2025, after market close. Management will hold a ...

Beta Bionics, Inc. (NASDAQ:BBNX) Q4 2025 Earnings Call Transcript February 18, 2026 Operator: Good day, and thank you for standing by. Welcome to the Beta Bionics Inc. Q4 and Full Year 2025 Earnings ...

Beta Bionics Inc (BBNX) reports a 54% increase in net sales and significant user base expansion, while addressing FDA compliance issues and anticipating short-term revenue headwinds.

Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the ...

IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release ...